Navigation Links
BIDMC scientists receive creativity awards from Prostate Cancer Foundation
Date:4/14/2009

BOSTON Two projects led by scientists at Beth Israel Deaconess Medical Center (BIDMC) have received funding from the Prostate Cancer Foundation (PCF) as part of their 2009 Creativity Awards program, which supports innovative ideas to improve the detection and treatment of prostate cancer.

The one-year awards were made to 10 projects at nine institutions throughout the U.S., with BIDMC the only institution in New England to be funded and the only institution to receive multiple awards.

PCF Creativity Awards were developed to aid the advancement of the world's most imaginative, new research ideas that are not currently funded by any existing government or private sources.

"We were impressed with the unique ideas represented by the applications we received. A rigorous peer review process vetted the 10 selected projects from a field of more than 300 applications representing 105 institutions in 11 countries," said Howard Soule, PhD, PCF executive vice president and chief scientist. "These awards feed our pipeline of compelling ideas to cultivate new solutions for the prostate cancer problem. Promising results will translate into better therapies for patients with advanced prostate cancer."

Towia Libermann, PhD, and Alan Rigby, PhD, will receive the Michael Vinecki Creativity Award for their work studying Ets factor binding sites on DNA, the first step in selecting candidate prostate cancer inhibitors. "We know that in 40 to 60 percent of prostate cancers, Ets factors are what lies behind both the initial disease and its progression," notes Libermann. He and Rigby will use a state-of-the-art computer-aided drug discovery platform developed in the Rigby laboratory to model the structure of these sites, with the ultimate goal of generating drug candidates to block prostate-cancer progression. Libermann is Director of the BIDMC Genomics and Proteomics Center and of the Dana-Farber/Harvard Cancer Center Proteomics Core in BIDMC's Division of Interdisciplinary Medicine and Biotechnology; Rigby is Interim Director of the Program in Drug Discovery and Target Validation in BIDMC's Center for Vascular Biology Research, Division of Molecular and Vascular Biology.

Pier Paolo Pandolfi, MD, PhD, Director of Research for BIDMC's Cancer Center will receive PCF's Dan Fogleberg Creativity Award for his work on cellular senescence. "Cellular senescence is a process whereby cancer cells 'go to sleep irreversibly,'" explains Pandolfi. Building on earlier work which identified a previously unknown form of senescence in prostate cancer cells, Pandolfi will use specialized animal models of prostate cancer to evaluate chemical compounds to achieve senescence in the cancer stem cell population, which is known to be extremely difficult to eradicate.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
2. Healthcare Data Services (HDS) Announces Contract with Beth Israel Deaconess Physician Organization (BIDPO) and Beth Israel Deaconess Medical Center (BIDMC)
3. BIDMC Dyslexia Research Lab celebrates 25th anniversary
4. Scientists discover way to jumpstart bones healing process
5. Scripps research scientists model 3D structures of proteins that control human clock
6. Scientists Identify Key Gene That Protects Against Leukemia
7. Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
8. Scientists Now Warn That White Wine Can Lead To Teeth Staining
9. Scientists Uncover New Weapon Against Huntingtons
10. Scientists show how a neuron gets its shape
11. Neuroscientists demonstrate link between brainwave acticity and visual perception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: